Nasdaq GlobeNewswire

Pomerantz Achieves Significant Victory for Investors in Petrobras Litigation

Del

NEW YORK, July 12, 2017 (GLOBENEWSWIRE)Pomerantz scored a significant victory for investors in In re Petrobras Sec. Litig. (2d Cir. July 7, 2017), one of the largest securities class actions pending in the United States. The case involves the alleged biggest corruption scandal in the history of Brazil, which, according to plaintiffs, has ensnared not only Petrobras' former executives but also Brazilian politicians, including former presidents and at least one third of the Brazilian Congress. According to plaintiffs, defendants' fraudulent scheme involved billions of dollars in kickbacks, tens of billions of dollars in overstated assets, as well as significant losses to Petrobras investors.

In a February 2, 2016 Opinion and Order, the District Court certified all the classes proposed by plaintiffs, encompassing not only purchasers of Petrobras American Depository Receipts, but also Petrobras bondholders who acquired securities pursuant to domestic transactions. Plaintiffs asserted claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Sections 11, 12(a)(2) and 15 of the Securities Act of 1933. Defendants appealed the District Court's certification opinion on multiple grounds, including for failure to satisfy the requirement of ascertainability and for failure to satisfy the burden of showing that the Petrobras securities at issue traded in efficient markets. The Second Circuit accepted the appeal and largely rejected defendants' arguments, sending the case back to the District Court for further proceedings.

The Second Circuit's decision is important and favorable precedent in several respects. First, in an issue of first impression, the Second Circuit squarely rejected defendants' invitation to adopt the heightened ascertainability requirement promulgated by the United States Court of Appeals for the Third Circuit, which would have required plaintiffs to demonstrate that determining membership in a class is "administratively feasible."  The Second Circuit's rejection of this standard is not only a victory for bondholders in securities class actions, but also plaintiffs in consumer fraud class actions and other class actions where documentation regarding Class membership is not readily attainable.

With respect to Petrobras' bondholders, the Court vacated the District Court's granting of class certification, but only to the extent that it did not perform an analysis regarding the impact of the Supreme Court's Morrison decision on the predominance requirement of class certification. Specifically, the Second Circuit required the District Court to analyze whether "common answers" to whether a transaction occurred in the United States could be ascertained via common proof.  The record in this case easily supports such a determination. Indeed, as the Second Circuit acknowledged, "the district court might properly certify one or more classes that capture all of the Securities holders who fall within the Classes as currently defined."

The Second Circuit also refused to adopt a requirement, urged by defendants, that all securities class action plaintiffs seeking class certification prove through direct evidence (i.e., via an event study) that the prices of the relevant securities moved in a particular direction in response to new information.  Reaffirming the Supreme Court's guidance in Halliburton II that the burden for plaintiffs seeking class certification "is not an onerous one," the Second Circuit rejected the notion that complicated event studies be submitted by Plaintiffs at the class certification stage. The Court agreed with plaintiffs that "event studies offer the seductive promise of hard numbers and dispassionate truth, but methodological constraints limit their utility in the context of single-firm analyses." 

Jeremy Lieberman, Managing Partner of Pomerantz commented: "We are very pleased with the Second Circuit's decision today, which provides important precedent for both domestic and foreign investors seeking redress for securities fraud impacting the U.S. capital markets. Plaintiffs allege that defendants engaged in a sweeping fraud lasting nearly a decade, which caused billions of dollars in losses to Petrobras investors, and hobbled the political and economic framework in Brazil, one of the largest economies in the world. This decision represents a victory for class action plaintiffs in securities, antitrust and consumer cases. Most significantly, the Second Circuit's decision allows this important case against Petrobras and other defendants to proceed apace, lifting the automatic stay imposed by the Second Circuit. As a result, we intend to ask Judge Rakoff to set a trial date as quickly as possible, to allow the defrauded class members to finally have their day in court."

The complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements regarding the company's business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) the company overstated its property, plant, and equipment on its balance sheet by overpricing contracts to certain companies relating to its refineries and operations and accepted kickbacks from construction companies approved for those contracts; (2) the company was receiving multi-billion dollar bribes from third-party contractors to secure contracts from Petrobras; (3) the company was in violation of its own Code of Ethics, as its employees and executives were routinely accepting bribes from certain construction companies; (4) the company's internal controls over financial reporting were ineffective and deficient; and (5) as a result of the foregoing, Petrobras' public statements were materially false and misleading at all relevant times.           

CONTACT:

Nicolas Tatin
Pomerantz LLP
ntatin@pomlaw.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Pomerantz LLP via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

IRYStec Signs Representation in Japan with Ryoden21.11.2018 15:00Pressemelding

MONTREAL, Nov. 21, 2018 (GLOBE NEWSWIRE) -- IRYStec Software Inc., the world leader in perceptual display processing technology, announced today that it has signed a representative agreement with Ryoden. Ryoden’s global expansion of its components and software solutions have enabled them to be a prominent electronics supplier in Japan, highly capable of leading IRYStec’s efforts to enter the Japanese automotive and consumer display device markets. “Ryoden’s vast experience and senior level relationships in both the Automotive OEM and tier 1 customer base along with their strong sales and technical presence across the whole of Japan will enable us to grow the adoption of our Perceptual Display Platform technology.”, said Simon Morris, CEO of IRYStec “We can see the need for perceptual display processing technology to enhance the display device experience especially for automotive displays where visibility of the display in sun light can be a safety concern. We are looking forward to gro

Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 201821.11.2018 14:30Pressemelding

WALTHAM, Mass., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Evercore ISI HealthCONx Conference on November 28, 2018 at 3:05 p.m. Eastern Time. The presentation will be webcast and accessible through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com. About Minerva Neurosciences Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301,

Valsoft reinforces global car rental management leadership with acquisition of Thermeon Worldwide Limited21.11.2018 13:00Pressemelding

MONTREAL, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Valsoft Corporation Inc. (“Valsoft”), a Montreal-based company that specializes in the acquisition and development of vertical market software businesses, is pleased to announce the acquisition of Thermeon Worldwide Ltd (“Thermeon”), a global industry-leading provider of car rental software headquartered in the UK with regional offices in the United States and Australia. Under the agreement, Valsoft will acquire Thermeon’s assets, including its brand name, CARS+. CARS+ provides the tools to manage the rental process from quotation and accounting to signature capture and credit card processing. CARS+ is used worldwide by most leading multinational brands and trusted local companies, at service counters, in fleet management, accounting, corporate management, and, most importantly, in Web and mobile customer interfaces. Thermeon, which was launched in 1967 under the guidance of Rollo Pickford, celebrated its 50th birthday in 2017. In the early 1

Anima Biotech Named U.S. Deal of the Year Winner at Lifestars™ Life Science Awards20.11.2018 16:17Pressemelding

Award recognizes the transformative potential of Anima’s $1B+ collaboration with Lilly BERNARDSVILLE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of drugs that specifically control protein translation, has been named winner of the “U.S. Deal of the Year” award at the 2018 Lifestars AwardsTM. “We are delighted to receive this award, which recognizes the power and potential of our Translation Control Therapeutics platform,” said Yochi Slonim, co-founder and chief executive officer of Anima Biotech. “Our deal with Lilly further validates our approach and our partnering strategy of creating exclusive collaborations around our partners’ chosen targets.” “Lifestars presented a fantastic opportunity to bring together a deserved audience and highlight the advances being made in our industry. It’s a testament to Anima Biotech’s efforts that this year’s judging faculty commended them in this manner,” said Neil Darkes, Co-CEO, LSX Ltd. And Lifestars. The int

Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics20.11.2018 15:00Pressemelding

US and EU patents for TissueCypher® cover methods for detecting risk of progression to esophageal cancer in Barrett’s esophagus patients PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Cernostics, developer of next-generation cancer diagnostics and prognostics, announced that it has received a U.S. Patent and a European Notice to Grant for the company’s TissueCypher® Barrett’s Esophagus Assay, adding protection to previously awarded foundational, platform patents granted in 2014. Earlier this month, Cernostics received notification from the European Patent Office that claims will be issued for its patent entitled “Systems and Compositions for Diagnosing Barrett’s Esophagus and Methods for Using the Same.” This notice comes on the heels of a recent issuance of a corresponding U.S. patent (U.S. Patent No. 10,018,631). Cernostics’ recent patent claims relate to the company’s clinical test for predicting disease progression in patients with BE and assessment of the likelihood that BE may fur

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom